Treatment-related myeloid neoplasms were present in 4 of our patients. The median time to diagnosis was 30 months.” Six non-relapse deaths occurred (16%), including progression of 2 cases of previous ...
Takeda ( TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize ...
Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme ...
or myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MPN-RS-T). Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data.
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with ...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...